港股異動丨“AI解決方案提供商”雲知聲首日上市一度大升33%
雲知聲(9678.HK)今日首日在港掛牌上市,午後升幅明顯擴大,一度大升33.17%至273港元。雲知聲是一家AI解決方案提供商,專注於在中國銷售用於日常生活及醫療相關應用場景的對話式AI產品及解決方案。公司的業務集中於通過以用户為中心的AI解決方案,提升運營效率、加強決策能力及提供更佳結果,為不同行業的客户提供動力。於往績記錄期間,雲知聲的收入主要來自銷售AI產品及解決方案。雲知聲的收入由2022年的6.01億元(人民幣,下同)增加至2024年的9.39億元,複合年增長率為25.0%;毛利由2022年的2.40億元增加至2024年的3.64億元,複合年增長率為23.3%。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.